Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$2.12 -2.8%	$2.04	$1.04 ▼ $3.73	$323.44M	1.18	2.15 million shs	871,971 shs
SNDL SNDL	$1.58 +13.7%	$1.30	$1.15 ▼ $2.40	$415.19M	3.4	1.96 million shs	8.40 million shs
TCRX TScan Therapeutics	$1.92 +6.1%	$1.50	$1.02 ▼ $7.89	$108.66M	0.97	408,501 shs	270,869 shs
VOR Vor Biopharma	$2.39 -4.4%	$0.67	$0.13 ▼ $3.29	$298.65M	2.04	4.76 million shs	11.00 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	-2.75%	-1.40%	+9.84%	+10.42%	-34.57%
SNDL SNDL	+13.67%	+27.42%	+22.48%	+18.80%	-26.51%
TCRX TScan Therapeutics	+6.08%	+32.41%	+23.87%	+47.69%	-71.51%
VOR Vor Biopharma	-4.40%	-10.49%	+1,212.47%	+241.43%	+151.58%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HRTX Heron Therapeutics	3.6773 of 5 stars	3.5	0.0	4.2	2.2	1.7	0.6
SNDL SNDL	3.0174 of 5 stars	3.5	3.0	0.0	1.9	0.0	1.3
TCRX TScan Therapeutics	3.6066 of 5 stars	3.5	5.0	0.0	2.1	3.3	0.6
VOR Vor Biopharma	3.926 of 5 stars	4.3	5.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	3.00	Buy	$5.00	135.85% Upside
SNDL SNDL	3.00	Buy	$3.63	129.43% Upside
TCRX TScan Therapeutics	3.00	Buy	$7.80	306.25% Upside
VOR Vor Biopharma	2.60	Moderate Buy	$5.63	135.51% Upside

Current Analyst Ratings Breakdown

Latest TCRX, HRTX, SNDL, and VOR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/9/2025	VOR Vor Biopharma	Citizens Jmp Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/9/2025	VOR Vor Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Perform	$6.00 ➝ $6.00
5/9/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
5/8/2025	VOR Vor Biopharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/8/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Neutral	$7.00 ➝ $0.40
5/7/2025	TCRX TScan Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $10.00
5/6/2025	TCRX TScan Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$7.00

(Data available from 7/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$148.52M	2.18	N/A	N/A	($0.22) per share	-9.64
SNDL SNDL	$671.81M	0.62	N/A	N/A	$3.15 per share	0.50
TCRX TScan Therapeutics	$4.42M	24.58	N/A	N/A	$4.26 per share	0.45
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
SNDL SNDL	-$69.18M	-$0.29	N/A	N/A	N/A	-11.48%	-9.02%	-7.60%	7/30/2025 (Estimated)
TCRX TScan Therapeutics	-$127.50M	-$1.09	N/A	N/A	N/A	-2,974.08%	-55.76%	-36.56%	8/11/2025 (Estimated)
VOR Vor Biopharma	N/A	-$1.51	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest TCRX, HRTX, SNDL, and VOR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	TCRX TScan Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	SNDL SNDL	-$0.04	N/A	N/A	N/A	$231.50 million	N/A
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
5/12/2025	Q1 2025	TCRX TScan Therapeutics	-$0.28	-$0.26	+$0.02	-$0.26	$1.62 million	$2.17 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million
5/1/2025	Q1 2025	SNDL SNDL	-$0.06	-$0.04	+$0.02	-$0.04	$214.60 million	$142.38 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDL SNDL	N/A	N/A	N/A	N/A	N/A
TCRX TScan Therapeutics	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	N/A	2.40	1.76
SNDL SNDL	0.10	4.62	3.12
TCRX TScan Therapeutics	0.15	8.55	8.55
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
SNDL SNDL	N/A
TCRX TScan Therapeutics	82.83%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	5.86%
SNDL SNDL	N/A
TCRX TScan Therapeutics	4.35%
VOR Vor Biopharma	2.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
SNDL SNDL	2,516	262.78 million	N/A	Optionable
TCRX TScan Therapeutics	100	56.59 million	54.13 million	Not Optionable
VOR Vor Biopharma	140	124.96 million	65.45 million	Not Optionable

TCRX, HRTX, SNDL, and VOR Headlines

Recent News About These Companies

Vor Biopharma Names Sandy Mahatme Chief Financial Officer

July 11, 2025 | marketwatch.com

Vor Biopharma: Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 11, 2025 | finanznachrichten.de

Vor Bio Appoints Veteran Biotech Executive Sandy Mahatme as Chief Financial Officer and Chief Business Officer

July 10, 2025 | globenewswire.com

Vor Biopharma Sees Unusually Large Options Volume (NYSE:VOR)

July 10, 2025 | americanbankingnews.com

Vor Biopharma: Not So Sure About This Surge, And Do Mind The Warrants

July 8, 2025 | seekingalpha.com

Biopharma layoffs for first half of the year jump 32% YOY

July 8, 2025 | fiercebiotech.comF

Vor Biopharma Target of Unusually High Options Trading (NYSE:VOR)

July 8, 2025 | marketbeat.com

Analysts Set Vor Biopharma Inc. (NYSE:VOR) Price Target at $5.63

July 8, 2025 | americanbankingnews.com

Boston’s biotech sector reels due to Trump health policy uncertainty

July 6, 2025 | ft.com

Vor Biopharma Inc. (NYSE:VOR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

July 5, 2025 | marketbeat.com

Vor Biopharma Q2 EPS Estimate Decreased by HC Wainwright

July 2, 2025 | marketbeat.com

Vor Bio Report Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 1, 2025 | globenewswire.com

HC Wainwright & Co. Upgrades Vor Biopharma (VOR)

June 30, 2025 | msn.com

Vor Biopharma's RemeGen Deal Paves Way For Multi-Billion Dollar Autoimmune Market

June 30, 2025 | benzinga.com

Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why

June 30, 2025 | zacks.com

Vor Biopharma (NYSE:VOR) Upgraded at HC Wainwright

June 30, 2025 | marketbeat.com

Vor Biopharma (NYSE:VOR) Gains Momentum S&P 500

June 27, 2025 | kalkinemedia.comK

Vor Biopharma Inc. Stock Grades - Barron's

June 27, 2025 | barrons.com

Vor Biopharma (NYSE:VOR) Stock Price Expected to Rise, Robert W. Baird Analyst Says

June 27, 2025 | marketbeat.com

Vor, with new CEO, changes course to target autoimmune disease

June 26, 2025 | biopharmadive.comB

After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept

June 26, 2025 | bioworld.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

TCRX, HRTX, SNDL, and VOR Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$2.12 -0.06 (-2.75%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.12 0.00 (-0.09%)

As of 04:00 AM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

SNDL NASDAQ:SNDL

$1.58 +0.19 (+13.67%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.58 0.00 (0.00%)

As of 04:00 AM Eastern

SNDL Inc. engages in the production, distribution, and sale of cannabis products in Canada. The company operates through Liquor Retail, Cannabis Retail, Cannabis Operations, and Investments segments. It engages in the cultivation, distribution, and sale of cannabis for the adult-use and medical markets; sells wines, beers, and spirits through wholly owned liquor stores; and private sale of recreational cannabis through wholly owned and franchised retail cannabis stores. In addition, the company produces and distributes inhalable products, such as flower, pre-rolls, and vapes. It offers its products under the Top Leaf, Sundial Cannabis, Palmetto, and Grasslands brands. The company was formerly known as Sundial Growers Inc. and changed its name to SNDL Inc. in July 2022. SNDL Inc. was incorporated in 2006 and is headquartered in Calgary, Canada.

TScan Therapeutics NASDAQ:TCRX

$1.92 +0.11 (+6.08%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$1.92 0.00 (-0.26%)

As of 07/14/2025 07:44 PM Eastern

TScan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also develops TSC-200, TSC-201, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors; and TSC-202 to treat solid tumors. In addition, the company develops vaccines for infectious diseases, such as SARS-CoV-2. It has collaborations with Novartis Institutes for BioMedical Research, Inc. To discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

Vor Biopharma NYSE:VOR

$2.39 -0.11 (-4.40%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.43 +0.04 (+1.67%)

As of 04:00 AM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time